公开(公告)号：EP1970398A1

公开(公告)日：2008-09-17

申请号：EP07103939.0

申请日：2007-03-12

申请人： Schering Oy

发明人： Tiitinen, Emilia ,  Jukarainen, Harri

IPC分类号： C08G77/46 ,  C08G77/08

CPC分类号： C08G77/08 ,  C08G77/46

摘要： The present invention relates to the use of tocopherol as a co-catalyst in the ring opening polymerisation of cyclic siloxanes. The present invention further relates to a method for manufacturing hydrophilic polysiloxanes, wherein a hydrido-containing cyclic siloxane is reacted with a hydrophilic molecule comprising a carbon-carbon double bond, having the general formula (I) H 2 C=CH-(CHR) n -O-(CHR 1 CR 2 R 3 ) m R 4 or (II) H 2 C=CH-(CHR) n -R 5 , wherein n is an integer from 0 to 4, m is an integer from 0 to 5, R, R 1 , R 2 , R 3 and R 4 are each independently hydrogen or a C 1 to C 6 alkyl, R 5 is a saturated cyclic hydrocarbon containing carbonyl group, in the presence of a first catalyst to obtain a monomer, and polymerising said monomer in the presence of a second catalyst and tocopherol as a co-catalyst.

摘要翻译： 本发明涉及在环状硅氧烷的开环聚合中使用生育酚作为助催化剂。 本发明还涉及亲水性聚硅氧烷的制造方法，其中含氢环状硅氧烷与包含碳 - 碳双键的亲水性分子反应，具有通式（I）H 2 C = CH-（CHR） n -O-（CHR 1 CR 2 R 3）m R 4或（II）H 2 C = CH-（CHR）n -R 5，其中n为0至4的整数，m为0至 5，R 1，R 2，R 3和R 4各自独立地为氢或C 1〜C 6烷基，R 5为含有羰基的饱和环状烃，在第一催化剂存在下，得到单体 ，并在第二催化剂和作为助催化剂的生育酚存在下聚合所述单体。

公开(公告)号：EP1629844B1

公开(公告)日：2007-09-12

申请号：EP04396049.1

申请日：2004-07-13

申请人： Schering Oy

发明人： Riihimäki, Teppo

IPC分类号： A61K31/58 ,  A61K31/565 ,  A61K9/08

CPC分类号： A61K31/565 ,  A61K9/0024 ,  A61K9/0034 ,  A61K9/0036 ,  A61K9/0039 ,  A61K31/58

公开(公告)号：EP1027037B1

公开(公告)日：2003-12-03

申请号：EP98945336.0

申请日：1998-09-18

申请人： Schering Oy

发明人： LEHTOLA, Veli-Matti ,  RANTALA, Eeva-Maria, Susanne ,  RANTALA, Pertti, Tapani

IPC分类号： A61K9/20 ,  A61K9/48 ,  A61K47/38 ,  A61K31/66

CPC分类号： A61K31/663 ,  A61K9/2009 ,  A61K9/2054

摘要： The object of the invention is a pharmaceutical preparation for oral use, especially a tablet, which as its active ingredient contains a pharmacologically acceptable salt of dichloromethylene bisphosphonic acid, i.e. a clodronate, especially disodium clodronate, and which as an excipient contains silicified microcrystalline cellulose. Further objects of the invention are a process for the manufacture of said pharmaceutical preparation, and the use of silicified microcrystalline cellulose for the manufacture of said pharmaceutical preparation.

公开(公告)号：EP1128811B1

公开(公告)日：2004-05-19

申请号：EP99954020.6

申请日：1999-10-26

申请人： Schering Oy

发明人： MARKKULA, Tommi ,  ALA-SORVARI, Juha ,  JUKARAINEN, Harri ,  LEHTINEN, Matti ,  RUOHONEN, Jarkko

IPC分类号： A61K9/00 ,  A61K38/22

CPC分类号： A61K9/0092 ,  A61K9/0024 ,  A61K9/0036 ,  A61K9/0039 ,  A61K31/565 ,  A61K31/569 ,  A61K31/57 ,  A61K31/575

摘要： The invention relates to a delivery device for the controlled release of a therapeutically active agent, especially a progestin or an estrogen, over a prolonged period of time, said device comprising a core comprising said therapeutically active agent, and a membrane encasing said core wherein said membrane is made of an elastomer. According to the invention, the elastomer is a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units.

公开(公告)号：EP1970397A1

公开(公告)日：2008-09-17

申请号：EP07103950.7

申请日：2007-03-12

申请人： Schering Oy

发明人： Tiitinen, Emilia ,  Jukarainen, Harri

IPC分类号： C08G77/06 ,  C08G77/46 ,  C08G77/08

CPC分类号： C08G77/46 ,  C08G77/06 ,  C08G77/08

摘要： The present invention relates to a method for manufacturing hydrophilic polysiloxanes, wherein a hydrido-containing cyclic siloxane is reacted with a hydrophilic molecule comprising a carbon-carbon double bond, having the general formula (l) H 2 C=CH-(CHR) n -O-(CHR 1 CR 2 R 3 ) m R 4 or (II) H 2 C=CH-(CHR) n -R 5 , wherein n is an integer from 0 to 4, m is an integer from 0 to 5, R, R 1 , R 2 , R 3 and R 4 are each independently hydrogen or a C 1 to C 6 alkyl, R 5 is a saturated cyclic hydrocarbon containing carbonyl group, in the presence of a first catalyst to obtain a monomer, and polymerising said monomer in the presence of a second catalyst. The present invention also relates to hydrophilic polysiloxanes and to elastomers based on these polysiloxanes.

摘要翻译： 本发明涉及一种亲水性聚硅氧烷的制造方法，其中含氢环状硅氧烷与包含碳 - 碳双键的亲水性分子反应，具有通式（I）H 2 C = CH-（CHR）n -O-（CHR 1 CR 2 R 3）m R 4或（II）H 2 C = CH-（CHR）n -R 5，其中n为0至4的整数，m为0至5的整数 R 1，R 2，R 3和R 4各自独立地为氢或C 1〜C 6烷基，R 5为饱和的含有羰基的烃基，在第一催化剂存在下，得到单体， 并在第二催化剂存在下使所述单体聚合。 本发明还涉及亲水性聚硅氧烷和基于这些聚硅氧烷的弹性体。

公开(公告)号：EP1629844A1

公开(公告)日：2006-03-01

申请号：EP04396049.1

申请日：2004-07-13

申请人： Schering Oy

发明人： Riihimäki, Teppo

IPC分类号： A61K31/58 ,  A61K31/565

CPC分类号： A61K31/565 ,  A61K9/0024 ,  A61K9/0034 ,  A61K9/0036 ,  A61K9/0039 ,  A61K31/58

摘要： The present invention relates to a delivery system comprising a core and a membrane encasing said core, wherein said core and membrane consist essentially of an elastomer composition and said core comprises at least one therapeutically active agent. The delivery system is characterized in that the membrane comprises at least one regulating agent. The invention also relates to a method for controlling the release of at least one therapeutically active agent from a delivery system.

摘要翻译： 本发明涉及包含芯和包围所述芯的膜的递送系统，其中所述芯和膜基本上由弹性体组合物组成，并且所述芯包含至少一种治疗活性剂。 递送系统的特征在于，膜包括至少一种调节剂。 本发明还涉及一种用于控制至少一种治疗活性剂从递送系统释放的方法。

公开(公告)号：EP1124902B1

公开(公告)日：2005-03-02

申请号：EP99931285.3

申请日：1999-06-11

申请人： Schering Oy

发明人： JUKARAINEN, Harri ,  MARKKULA, Tommi ,  ALA-SORVARI, Juha ,  LEHTINEN, Matti ,  RUOHONEN, Jarkko

IPC分类号： C08L83/12 ,  C08G77/46 ,  A61K9/58

CPC分类号： C08L83/12 ,  A61K9/0024 ,  A61K9/0036 ,  A61K9/0039 ,  A61K9/2027 ,  A61K9/2031

公开(公告)号：EP1438942A1

公开(公告)日：2004-07-21

申请号：EP03000987.2

申请日：2003-01-17

申请人： Schering Oy

发明人： Haapakumpu, Timo ,  Jukarainen, Harri ,  Ala-Sorvari, Juha

IPC分类号： A61F11/00 ,  A61K9/00 ,  A61L31/06 ,  A61L31/16

CPC分类号： A61K9/0046 ,  A61K9/0043 ,  A61L31/06 ,  A61L31/16 ,  Y10S514/953 ,  C08L83/04

摘要： The invention relates to an otorhinological delivery device comprising at least one pharmaceutically active agent. According to the invention the device comprises a core comprising said at least one pharmaceutically active agent wherein said core is made of an elastomer composition selected from the group consisting of poly(dimethylsiloxane), a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units, a siloxane-based elastomer comprising poly(alkylene oxide) groups and mixtures thereof.

摘要翻译： 本发明涉及包含至少一种药物活性剂的心律学递送装置。 根据本发明，该装置包括一种包含所述至少一种药物活性剂的核心，其中所述核心是由选自聚（二甲基硅氧烷），含有3,3,3-三氟丙基 连接到硅氧烷单元的Si原子的基团，包含聚（环氧烷）基团的硅氧烷基弹性体及其混合物。

公开(公告)号：EP1427390A1

公开(公告)日：2004-06-16

申请号：EP02753112.8

申请日：2002-08-27

申请人： Schering Oy

发明人： HAAPAKUMPU, Timo ,  ALA-SORVARI, Juha ,  AALTONEN, Marko ,  KEINÄNEN, Antti ,  AHOLA, Manja

IPC分类号： A61K9/00 ,  A61M31/00 ,  A61F6/14 ,  A61F6/06

CPC分类号： A61K9/0024 ,  A61K9/0036 ,  A61K9/0039 ,  A61K9/209 ,  A61K9/2853 ,  A61K9/2886 ,  A61K31/56

摘要： The invention relates to a delivery system comprising at least one core and a membrane. The core and the membrane consist of an elastomer composition comprising e.g poly (dimethylsiloxane), a siloxane-based elastomer comprising 3,3,3-trifluorpropyl groups attached to the Si-atoms of the siloxane units and/or poly(alkylene oxide) groups, present as alkoxy-terminated grafts or blocks linked to the polysiloxane units by silicon-carbon bonds, or as a mixture of these forms. The delivery system is preferably an implant or an intrauterine, intracervical or intravaginal system.

公开(公告)号：EP1328277A1

公开(公告)日：2003-07-23

申请号：EP01980564.7

申请日：2001-10-26

申请人： Schering Oy

发明人： ÖSTERMAN, Thua ,  HANNUNIEMI, Ritva ,  HENTUNEN, Teuvo ,  LIUKKO-SIPI, Sirpa ,  NIKANDER, Hannu ,  SELANDER, Katri,UAB Cancer Center, WTI Room T558 ,  SELLMAN, Raija ,  VÄÄNÄNEN, Kalervo

IPC分类号： A61K31/662 ,  C07F9/58 ,  C07F9/40

CPC分类号： A61K45/06 ,  A61K31/662

摘要： The present invention is directed to a method for the preparation of a pharmaceutical composition having osteoclast formation inhibiting or suppressing activity, characterized in that, as the active agent, a compound of the formula (I) is used, in which formula Q1 is hydrogen, hydroxyl, halogen, amino -NH2, or -OR', wherein R' is C1-C4-alkyl or acyl, Q2 is straight or branched alkyl, hydroxyalkyl or aminoalkyl, or a corresponding unsaturated group optionally substituted at the hydroxy or amino group, or a unsubstituted or substituted, saturated or unsaturated cycloalkyl, which can be bound to the methylene carbon over a straight or branched alkylene group, or is the group (a) wherein Y is a saturated or unsaturated heterocyclic group, or a carbocyclic aromatic group, X is a bond, O, S or NR3, wherein R3 is hydrogen or a protecting group, especially lower alkyl, acyl, aryl or arylalkyl, and n is an integer 0 to 6, R?1 and R2¿ are independently hydrogen or C1-C4-alkyl, or it is halogen, and the groups R1 to R4 are the same or different, and mean an alkyl group with 1 - 5 carbon atoms, whereby one or two of the groups R1 to R4 can also mean hydrogen, or a pharmacologically acceptable salt thereof.